Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazine |
| |
| Authors: | Zhou Yuefen Webber Stephen E Murphy Douglas E Li Lian-Sheng Dragovich Peter S Tran Chinh V Sun Zhongxiang Ruebsam Frank Shah Amit M Tsan Mei Showalter Richard E Patel Rupal Li Bin Zhao Qiang Han Qing Hermann Thomas Kissinger Charles R Lebrun Laurie Sergeeva Maria V Kirkovsky Leo |
| |
| Institution: | Anadys Pharmaceuticals, Inc., 3115 Merryfield Row, San Diego, CA 92121, USA. |
| |
| Abstract: | 5-Hydroxy-3(2H)-pyridazinone derivatives were investigated as inhibitors of genotype 1 HCV NS5B polymerase. The synthesis, structure-activity relationships (SAR), metabolic stability, and structure-based design approach for this new class of compounds are discussed. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
